Express Pharma

Amgen bets on ChemoCentryx’s rare disease drug in $3.7 billion deal

Amgen has been facing stiff competition for its top-selling arthritis drug, Enbrel, from newer branded treatments and patents for the therapy are expected to expire in 2029

2 229